International Assets Investment Management LLC Has $10.75 Million Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

International Assets Investment Management LLC lifted its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 207.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,994 shares of the medical research company's stock after buying an additional 52,609 shares during the period. International Assets Investment Management LLC owned approximately 0.07% of Quest Diagnostics worth $10,754,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Quest Diagnostics by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company's stock worth $1,917,961,000 after buying an additional 636,301 shares during the last quarter. American Century Companies Inc. increased its holdings in Quest Diagnostics by 12.3% in the 3rd quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company's stock valued at $433,153,000 after purchasing an additional 388,162 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Quest Diagnostics by 5.6% in the 3rd quarter. Victory Capital Management Inc. now owns 3,414,514 shares of the medical research company's stock valued at $416,093,000 after purchasing an additional 180,889 shares in the last quarter. Wellington Management Group LLP increased its holdings in Quest Diagnostics by 14.6% in the 3rd quarter. Wellington Management Group LLP now owns 2,613,793 shares of the medical research company's stock valued at $318,517,000 after purchasing an additional 333,947 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Quest Diagnostics by 36.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,001,347 shares of the medical research company's stock valued at $243,884,000 after purchasing an additional 538,377 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares of the company's stock, valued at $4,843,610.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the firm's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the transaction, the senior vice president now owns 38,478 shares of the company's stock, valued at $4,843,610.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Catherine T. Doherty sold 5,557 shares of the firm's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $126.57, for a total transaction of $703,349.49. Following the completion of the sale, the executive vice president now owns 69,599 shares in the company, valued at approximately $8,809,145.43. The disclosure for this sale can be found here. Insiders have sold 15,150 shares of company stock valued at $1,913,202 over the last quarter. Insiders own 1.70% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on DGX shares. Leerink Partnrs reiterated a "market perform" rating on shares of Quest Diagnostics in a report on Monday, February 26th. SVB Leerink began coverage on shares of Quest Diagnostics in a research report on Monday, February 26th. They issued a "market perform" rating and a $135.00 price objective for the company. TheStreet cut shares of Quest Diagnostics from a "b-" rating to a "c" rating in a research report on Monday, February 5th. Truist Financial reissued a "hold" rating and issued a $145.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, March 20th. Finally, Barclays began coverage on shares of Quest Diagnostics in a research report on Wednesday, January 3rd. They issued an "equal weight" rating and a $145.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $144.18.

Quest Diagnostics Stock Down 1.1 %

Shares of DGX stock traded down $1.49 during trading hours on Friday, hitting $128.53. 720,163 shares of the company were exchanged, compared to its average volume of 878,920. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31. Quest Diagnostics Incorporated has a one year low of $119.59 and a one year high of $148.62. The business's 50-day simple moving average is $128.19 and its two-hundred day simple moving average is $130.61. The stock has a market capitalization of $14.27 billion, a price-to-earnings ratio of 17.16, a P/E/G ratio of 2.81 and a beta of 0.91.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.11 by $0.04. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The business had revenue of $2.29 billion for the quarter, compared to analysts' expectations of $2.25 billion. During the same quarter last year, the company posted $1.98 earnings per share. The company's quarterly revenue was down 1.9% compared to the same quarter last year. Sell-side analysts predict that Quest Diagnostics Incorporated will post 8.75 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Friday, April 5th. This represents a $3.00 dividend on an annualized basis and a yield of 2.33%. This is a boost from Quest Diagnostics's previous quarterly dividend of $0.71. Quest Diagnostics's dividend payout ratio (DPR) is currently 37.92%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.